Price
$41.39+19.76%Social Signal Score
Analyst Ratings
19 analystsRevenue
$153.60M+300.64%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael H. Carrel
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 1,350
- Beta
- 1.26
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 10.92
Financials
Revenue
$153.60M+300.6%Net Income
$8.96MEBITDA
$3.18MFree Cash Flow
$18.43MEPS (diluted)
$0.18Shares Outstanding (diluted)
49.09M+54.8%Operating Expenses
$108.96MCash & Debt
$167.79MReturn of Capital
$314.0KRevenue by Segment (annual)
$2.45MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $534.53M | $-11.45M | $-0.24 |
| 2024 | $465.31M | $-44.70M | $-0.95 |
| 2023 | $399.25M | $-30.44M | $-0.66 |
| 2022 | $330.38M | $-46.47M | $-1.02 |
| 2021 | $274.33M | $50.20M | $1.11 |
| 2020 | $206.53M | $-48.16M | $-1.14 |
| 2019 | $230.81M | $-35.19M | $-0.94 |
| 2018 | $201.63M | $-21.14M | $-0.62 |
| 2017 | $174.72M | $-26.89M | $-0.83 |
| 2016 | $155.11M | $-33.34M | $-1.05 |
| 2015 | $129.75M | $-27.21M | $-0.97 |
| 2014 | $107.45M | $-16.21M | $-0.61 |
| 2013 | $81.89M | $-11.46M | $-0.56 |
| 2012 | $70.25M | $-7.53M | $-0.47 |
Valuation
ATRChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-78.57%Social Signal Score
Mentions (7)
- Newsfool.com·23d ago·Negative
AtriCure CTO Sells 3,657 Shares The transaction was valued at $201,000. The sale represented 2% of the insider's direct equity holdings prior to the transaction.
View source ↗ - Newszacks.com·26d ago·Positive
AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue? AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗ - Newsseekingalpha.com·46d ago·Positive
AtriCure: Promising Cardiovascular Surgical Platform AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.
View source ↗ - Newsgurufocus.com·55d ago·Positive
A Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95 On August 11, 2026, AtriCure Inc (ATRC) shares rose 3.1% to a current price of $42.95, maintaining a strong performance in the market. Over the past week, the s
View source ↗ - Newsfool.com·59d ago·Neutral
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduced the director's total equity holdings by 20%, based on holdings reported in the Form 4.
View source ↗ - Newsfool.com·59d ago·Negative
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5. The sale resulted in a 14% reduction in the director's total direct equity holdings in the company.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.01 per share
Typical surprise +67.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$0.18 vs $-0.00beat
- Tue, May 5$0.00 vs $-0.07beat
- Tue, Feb 17$0.06 vs $-0.04beat
- Wed, Oct 29$-0.01 vs $-0.11beat
- Tue, Jul 29$-0.13 vs $-0.15beat
- Tue, Apr 29$-0.14 vs $-0.25beat
Estimates and results for ATRC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ATRC officers and directors.
- Bought
- —
- Sold
- $5.3m
0 trades
24 trades
- Privitera Salvatoresold
- Groves Regina Esold
- Privitera Salvatoresold
- Privitera Salvatoresold
- Dahlquist Karl S.sold
- Prange Karensold
- Yuen Maggiesold
- Noznesky Justin Jsold
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Sep 11, 2026 (22d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2025 (34d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 15, 2024 (27d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (21d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 15, 2021 (37d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed May 13, 2020 (13d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 16, 2020 (16d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Mar 10, 2020 (18d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed Dec 11, 2019 (34d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed Jul 12, 2019 (15d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed Jun 18, 2019 (41d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.